MedTrace Logo

Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19

NCT04545047 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5044

Last updated 2024-04-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).

Conditions

  • Coronavirus Disease 2019 (COVID-19)

Interventions

BIOLOGICAL

COVID-19 convalescent plasma

Convalescent plasma collected from individuals who have recovered from COVID-19

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Nicholas L. Smith, PhD · VA Puget Sound Health Care System Seattle Division, Seattle, WA

  • Michael J Gaziano, MD MPH · VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2021-10-01
Completion
2021-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04545047 on ClinicalTrials.gov